KRAS and lung adenocarcinoma: Nevertheless, recent studies have reported that KRAS mutant lung adenocarcinoma resistance to first-generation tyrosine kinase inhibitors (TKIs) is not due to downstream KRAS activation but rather to activation of other ErbB family members [13].